Tag Archive for: Adcendo

Adcendo ApS Announces Extension of Series A Financing to 82M EUR to Ensure Broad Development of its First-in-class ADC Pipeline

Series A Financing extension led by Pontifax Venture Capital and existing investors Novo Holdings and Ysios Capital, raising an additional 31M EUR Funds will be used to ensure broad pan-sarcoma development of lead ADC asset uPARAP and to further advance second ADC pipeline asset Ohad Hammer, partner at Pontifax Venture Capital, joins Board of Directors […]

Optimum’s clients are at the forefront of Cancer research

  World Cancer Day is a moment when all of us stop and think of the impact that cancer has on our lives. As the second-leading cause of death worldwide, with 10 million people dying from cancer every year, cancer is a very present healthcare threat. [tag] Macmillan Cancer Support estimates that there are currently […]

Adcendo ApS Announces License Agreement with Duality Biologics on Next-generation ADC Platform

Adcendo licenses Duality’s DITAC (Duality Immune Toxin Antibody Conjugates) linker/payload platform for its lead uPARAP-ADC program Agreement based on synergies between Adcendo and Duality in generating breakthrough ADCs in hard-to-treat cancers Copenhagen, Denmark, January 5, 2023 – Adcendo ApS (“Adcendo”), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of […]

BioInnovation Institute announces latest cohort of companies entering Venture Lab program

BioInnovation Institute (BII), an international commercial non-profit foundation incubating and accelerating world-class life science research, today announces the latest cohort of participants in its Venture Lab acceleration program for early-stage companies. The eight ventures are strategically aligned with BII’s focus, developing ground-breaking scientific initiatives across three specialist areas – therapeutics, bioindustrials and health tech. Read more

Novo Seeds Provides Business Update on a Record Year – Building Exceptional Companies for Global Impact

Over US$ 550 million raised by portfolio companies in 2021 IO Biotech IPO on US NASDAQ Forendo Pharma acquired for nearly US$ 1 billion Muna launched with world-leading science to advance latest scientific breakthroughs in neuroscience Adcendo raised US$ 60 million Series A to deliver next-generation Antibody-Drug Conjugates Hemab raised US$ 50 million Series A to […]